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ABSTRACT
Postherpetic neuralgia (PHN) is one of the most common and important complications of severe varicella-zoster infection, especially occurring in 
20% of the elderly patients. A 59-year-old female presented with pain in the right sacral region for the past 3 months. The pain was preceded by 
herpes zoster. She was diagnosed as a case of Sacral PHN. We administered paramedian approach of ganglion impar block with 10 ml of 0.25% 
bupivacaine with 8 mg dexamethasone which resulted in immediate adequate pain relief. On follow-up after 8 weeks, the pain score continued to be 
less with 3/10. No complications were encountered. There was no sensory loss. We conclude that ganglion impar block with a combination of local 
anesthetic and steroid is a viable treatment option for sacral PHN.
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INTRODUCTION
Postherpetic neuralgia (PHN) is one of the most resistant chronic pain 
problems, usually affecting elderly patients. The pain of PHN usually 
follows the typical dermatomal distribution of the erythematous 
rash earlier caused by herpes zoster. Commonly unilateral thoracic 
dermatomes and the trigeminal nerve, especially the ophthalmic 
branch, are frequently affected [1], but sacral dermatome is not 
frequent. Despite adequate treatment, 20% suffer from the pain of the 
disease. Anticonvulsants, sympathetic, epidural blocks, and blocks of 
ganglion impar have been used with variable success [2].
Tricyclic antidepressants provide the best chance of relief with the few 
side effects. This is given along with anticonvulsant (carbamazepine, 
valproic acid, or phenytoin), but the possibility of liver dysfunction 
or bone marrow depression should be kept in mind. Gabapentin is 
effective for the management of PHN. It does not carry the risk of organ 
dysfunction which is seen with older anticonvulsants. Opioids may 
cause constipation in older patients with few benefits. Most studies fail 
to show much benefit from spinal cord stimulation. Transcutaneous 
electrical nerve stimulation (TENS) may help in occasional patients, 
but cause aggravation of pain in patients with severe allodynia, and is 
not beneficial if there is considerable cutaneous sensory loss. Topical 
capsaicin is occasionally helpful but can aggravate the pain in some 
individuals [3,4]. Transdermal lidocaine patches can be helpful in some 
patients. The ganglion impar [5] (ganglion of Walther) is the most 
caudal part of the sympathetic trunks. The lowest two sympathetic 
ganglia of the pelvis often fuse forming one ganglion in the midline 
anterior to the coccyx. We wished to block the sympathetic ganglion to 
get the desired pain relief.
CASE REPORT
A 59-year-old female came to our hospital with the complaints of pain 
in the right sacral region, which was constant, neuropathic in nature, 
gradually increased in intensity for the past 3 months. Earlier, she had 
clinical features of herpes zoster. She was treated with carbamazepine, 
topical acyclovir patches, and neurovitamins, after 3 weeks. 
A combination therapy with gabapentin and amitriptyline was changed 
for 3 weeks. Oral tramadol was added after 20 days. The combination 
of all these drugs produced less relief. The daytime sedation was too 
high to continue such combination. There was no improvement in pain. 
There was a mild hyperalgesia on touching the lesions (Fig. 1).
The visual analog score (VAS) remained at 7/10. She did not have any 
other lesions over genitals, skin, and mouth. We administered ganglion 
impar block with 10 ml of 0.25% bupivacaine with 8 mg dexamethasone 
by Raj’s paramedian approach. After 20 min, the patient was pain free 
(VAS - 1–2/10). There was no sensory loss. After 4 weeks, the patient 
came for follow-up and the pain score continued to be less with a VAS 
score of 3/10. No complications were noted. The only carbamazepine 
regimen of 200 mg in the night was continued.
DISCUSSION
Varicella-zoster virus, a member of the herpes virus family, is a significant 
cause of morbidity despite immunization. The incidence of varicella 
(chickenpox) is over 4 million cases per year, whereas the incidence of 
herpes zoster is 300,000 cases per year. Primary infection with varicella-
zoster virus results in varicella (i.e., chickenpox) which is followed by a 
latent phase where the virus remains sequestered in dorsal root ganglia 
of the trigeminal ganglion remaining dormant; however, it may be 
reactivated anytime, leading to herpes zoster (shingles). Reactivation 
may be triggered by infection, immunosuppression, trauma, irradiation, 
malignancy, and advancing age. Herpes zoster is characterized as 
severe pain in one or more dermatomes usually followed by a vesicular 
skin eruption 7–10 days later. Persistence of painful symptoms for 
4–6 weeks after the termination of the acute phase of infection is 
referred to as PHN. The prevalence of PHN is around 9–45% of all cases 
of herpes zoster [6]. Early institution of sympathetic blockade has 
been advocated to decrease the incidence and severity of PHN [7]. This 
therapy remains controversial because a direct correlation between 
sympathetic blockade and prevention of PHN has not been proven by 
randomized prospective trials. The ganglion impar is the fused terminal 
end of the paravertebral sympathetic chain and is found at the level of 
the sacrococcygeal junction. Neural blockade of the ganglion impar has 
been advocated as a means of managing intractable pelvic and perineal 
pain in cancer patients [8]. A review of the literature reveals very limited 
information on the usefulness of blockade of the ganglion impar for pain 
other than that of neoplastic origin. The original technique for blockade 
of the ganglion impar described by Plancarte et al. [9] involves a midline 
© 2019 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2019.v12i2.29423
Case Report
16
Asian J Pharm Clin Res, Vol 12, Issue 2, 2019, 15-16
 Parthasarathy and Batcha 
approach through the anococcygeal ligament with advancement of 
the needle tip cephalad to the anterior surface of the sacrococcygeal 
ligament. This technique involves placing one or two bends near the tip 
of the needle to more easily approximate the location of the ganglion. 
However, a gently curved needle has also been advocated to negotiate 
around the natural curve of the coccyx. Insertion of a finger in the 
rectum has been advocated as a safeguard against perforation of the 
rectum because it lies in close proximity to the solitary ganglion. This 
technique can be quite uncomfortable in a patient with rectal pathology 
and also makes it difficult to maintain sterility during the procedure. 
Wemm Jr. and Saberski [10] advocate passing directly through the 
sacrococcygeal ligament to reach the ganglion impar. This approach can 
be useful in patients with normal anatomy but may prove challenging 
in patients with arthritic changes in the bones and calcification of the 
ligaments of the sacrum and coccyx. Raj et al. [8] briefly described a 
paramedian approach to the ganglion which was administered by 
us. Huang [11] recently described a lateral approach to the ganglion 
approaching from below the transverse process of the coccyx inferior 
to the level of the sacrococcygeal junction. The pain caused by PHN may 
involve both peripheral and central mechanisms. This understanding 
likely explains why PHN is so difficult to treat when the lesion is not 
confined to an accessible dermatome like intercostal nerve where we 
can administer the selective intercostal nerve block with ease. However, 
when the lesion is in remote area-like sacral region where targeting a 
single nerve is not possible, we planned to target the sympathetic 
component as was done in our case. It also stresses the importance of 
multiple modes of therapy. The role of corticosteroids [12] in pain relief 
for this patient is uncertain. Corticosteroid injections with nerve blocks 
have had unpredictable and limited success in the treatment of PHN. 
Sacral dermatomal distribution of zoster and PHN is unusual but can 
lead to severe and disabling pain. Blockade of the ganglion impar may 
play a significant role in the treatment of this disabling pain. Further, 
investigation is needed to determine efficacy of this sympathetic block 
in the treatment of the pain of zoster and PHN in the sacral dermatomes. 
Due to the low incidence of complications with blockade of the ganglion 
impar, it may have a role in early aggressive therapy of zoster in the 
sacral dermatomes. As such, there are only few case reports [13] in 
literature in the management of sacral PHN by ganglion impar block. 
Hence, this case is reported for its rarity. The commonly used outpatient 
opioid is tramadol, and the use of the same drug to counter pain in PHN 
may not be predictable in all cases due to genetic reasons [14,15]. By 
blocking the sympathetics, we can overcome the problem mentioned 
above. Even though ultrasound [16] can help in administration of the 
block, we gave it by the classical approach only.
CONCLUSION
We conclude that ganglion impar blockade is a viable treatment option 
for sacral PHN. As the involved sacral region is not amenable to be 
easily targeted like intercostal area, the blockade of ganglion impar is a 
definite therapeutic modality.
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Fig. 1: Sacral postherpetic lesions
